Skip to content

Study · Animal study (in vivo) · mouse · 1989

4 results

Influence of thymic preparations on the result of experimental infection with Taenia crassiceps (Zeder, 1800) in ICR mice.

Hermánek J, Prokopic J

Folia parasitologica1 Jan 1989Cited by 4 (Europe PMC)

PMID2488049 (opens in a new tab)PepBankPUB-02488049
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In infected mice, a single Thymalin dose reduced peritoneal cysticerci numbers by 54.9% compared with controls.

    In plain wordsIn infected mice, a single Thymalin dose reduced parasite cyst numbers by 54.9% compared with controls.

    Peptide
    Thymalin
    Outcome
    DecreasePeritoneal cysticerci number
    Study

    mousen: not reported in source

    ICR mice infected with Taenia crassiceps
    Comparator
    Controls
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    100 micrograms per mouse · Subcutaneous · Single application at the day of infectionAs given in this study (mouse).

    Measurements

    Cysticerci reduction
    54.9%
    versus controls

    Source sentences

    Summary
    A single subcutaneous application of 100 micrograms of Thymalin per mouse at the day of infection resulted in a decrease (by 54.9%) in the number of cysticerci in peritoneal cavity of experimental mice compared with the controls.
    1 context sentence
    Summary · context
    Thymalin (Thymarin) and T-activin--thymic preparations of polypeptidic character--were used for influencing the parasitic infection in a model system mouse--Taenia crassiceps.

Studies that did not test the peptide alone3

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 02AnimalNot a test of Thymalin aloneAnimal study (in vivo)Efficacy outcome

    In infected mice, Thymalin with larval homogenate significantly increased specific serum antibody levels.

    In plain wordsIn infected mice, Thymalin with parasite larval homogenate increased specific antibody levels.

    Peptide
    Thymalin
    Outcome
    IncreaseSpecific serum antibodies
    Study

    mousen: not reported in source

    ICR mice infected with Taenia crassiceps
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Administration of Thymalin with T. crassiceps larval homogenate at various intervals before and after infection resulted in a statistically significant increase of the level of specific antibodies in the serum of infected mice, this increase, however, did not correlate with the corresponding protective effect.
    1 context sentence
    Summary · context
    Thymalin (Thymarin) and T-activin--thymic preparations of polypeptidic character--were used for influencing the parasitic infection in a model system mouse--Taenia crassiceps.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 03AnimalNot a test of Thymalin aloneAnimal study (in vivo)Mechanism

    In infected mice given Thymalin with larval homogenate, increased specific antibodies did not correlate with protective effects.

    In plain wordsIn infected mice given Thymalin with larval homogenate, higher specific antibody levels were not linked to protection.

    Peptide
    Thymalin
    Outcome
    No significant changeAntibody association with protection
    Study

    mousen: not reported in source

    ICR mice infected with Taenia crassiceps
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Administration of Thymalin with T. crassiceps larval homogenate at various intervals before and after infection resulted in a statistically significant increase of the level of specific antibodies in the serum of infected mice, this increase, however, did not correlate with the corresponding protective effect.
    1 context sentence
    Summary · context
    Thymalin (Thymarin) and T-activin--thymic preparations of polypeptidic character--were used for influencing the parasitic infection in a model system mouse--Taenia crassiceps.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  3. 04AnimalNot a test of Thymalin aloneAnimal study (in vivo)Mechanism

    In infected mice across the study, antibody levels, spleen index and cysticerci numbers showed no detected correlation.

    In plain wordsIn infected mice across the study, antibody levels, spleen index and parasite cyst numbers showed no detected link.

    Peptide
    Thymalin
    Outcome
    No significant changeAntibody, spleen index and parasite burden correlation
    Study

    mousen: not reported in source

    ICR mice infected with Taenia crassiceps
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Correlation of the level of specific antibodies in the serum of infected mice, value of spleen index and number of T. crassiceps cysticerci in peritoneal cavity of mice was not detected.
    1 context sentence
    Summary · context
    Thymalin (Thymarin) and T-activin--thymic preparations of polypeptidic character--were used for influencing the parasitic infection in a model system mouse--Taenia crassiceps.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.